[{"orgOrder":0,"company":"Infant Bacterial Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pediatrics\/Neonatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Lactobacillus Reuteri","moa":"","graph1":"Pediatrics\/Neonatology","graph2":"Phase I","graph3":"Infant Bacterial Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Pediatrics","amount2New":0,"dosageForm":"","sponsorNew":"Infant Bacterial Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Infant Bacterial Therapeutics \/ Not Applicable"}]

Find Pediatrics/Neonatology Clinical Drug Pipeline Developments & Deals

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : IBP-1016 (lactobacillus reuteri) is known to have four interactive mechanisms of action that is gut microbiome and receives FDA orphan drug designation for gastroschisis.

                          Brand Name : IBP-1016

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 03, 2023

                          Lead Product(s) : Lactobacillus Reuteri

                          Therapeutic Area : Pediatrics/Neonatology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank